Alto Neuroscience (NYSE:ANRO) Stock Rating Lowered by Wall Street Zen

by · The Markets Daily

Alto Neuroscience (NYSE:ANRO – Get Free Report) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

Several other equities research analysts have also recently issued reports on the stock. Wedbush raised their target price on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Wolfe Research assumed coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They set an “outperform” rating for the company. Zacks Research cut Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Robert W. Baird lowered their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Finally, Chardan Capital restated a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and an average price target of $35.25.

Check Out Our Latest Stock Report on ANRO

Alto Neuroscience Price Performance

ANRO opened at $27.09 on Friday. The company’s 50-day simple moving average is $24.11 and its two-hundred day simple moving average is $21.94. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The stock has a market capitalization of $950.87 million, a P/E ratio of -11.20 and a beta of 1.04. Alto Neuroscience has a 52-week low of $3.00 and a 52-week high of $28.85.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, analysts predict that Alto Neuroscience will post -3.14 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Commodore Capital LP purchased a new stake in Alto Neuroscience during the fourth quarter valued at approximately $32,453,000. Perceptive Advisors LLC boosted its stake in shares of Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after acquiring an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the last quarter. Spruce Street Capital LP grew its position in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after acquiring an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC bought a new stake in shares of Alto Neuroscience during the 4th quarter valued at $18,433,000.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

Recommended Stories